JP2009525055A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525055A5 JP2009525055A5 JP2008553510A JP2008553510A JP2009525055A5 JP 2009525055 A5 JP2009525055 A5 JP 2009525055A5 JP 2008553510 A JP2008553510 A JP 2008553510A JP 2008553510 A JP2008553510 A JP 2008553510A JP 2009525055 A5 JP2009525055 A5 JP 2009525055A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- conservative amino
- acid substitutions
- csggkvldc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 273
- 238000006467 substitution reaction Methods 0.000 claims 261
- 206010028980 Neoplasm Diseases 0.000 claims 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 201000011510 cancer Diseases 0.000 claims 19
- 238000000034 method Methods 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 10
- 210000001365 lymphatic vessel Anatomy 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 7
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 230000003211 malignant effect Effects 0.000 claims 4
- 210000002307 prostate Anatomy 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000035168 lymphangiogenesis Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 101710085003 Alpha-tubulin N-acetyltransferase Proteins 0.000 claims 1
- 101710085461 Alpha-tubulin N-acetyltransferase 1 Proteins 0.000 claims 1
- 101800002011 Amphipathic peptide Proteins 0.000 claims 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims 1
- 101150019028 Antp gene Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims 1
- TWOFBVMVSYSAFW-UFUGHDFUSA-N N'-(3-aminopropyl)butane-1,4-diamine (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol guanidine Chemical compound NC(N)=N.NC(N)=N.NCCCCNCCCN.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 TWOFBVMVSYSAFW-UFUGHDFUSA-N 0.000 claims 1
- 108010088535 Pep-1 peptide Proteins 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 101710175714 Tyrosine aminotransferase Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 claims 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 108010025307 buforin II Proteins 0.000 claims 1
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 210000005073 lymphatic endothelial cell Anatomy 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- -1 pVEC Proteins 0.000 claims 1
- 108010043655 penetratin Proteins 0.000 claims 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims 1
- 230000000861 pro-apoptotic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 claims 1
- 108010062760 transportan Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76417506P | 2006-02-01 | 2006-02-01 | |
| PCT/US2007/061480 WO2007090194A2 (en) | 2006-02-01 | 2007-02-01 | Lymphatic zip codes in tumors and pre-malignant lesions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009525055A JP2009525055A (ja) | 2009-07-09 |
| JP2009525055A5 true JP2009525055A5 (https=) | 2010-03-25 |
Family
ID=38328164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008553510A Pending JP2009525055A (ja) | 2006-02-01 | 2007-02-01 | 腫瘍および前癌性病変におけるリンパ管のジップコード |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US7919466B2 (https=) |
| EP (1) | EP1996607A4 (https=) |
| JP (1) | JP2009525055A (https=) |
| CA (1) | CA2638807A1 (https=) |
| WO (1) | WO2007090194A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1996607A4 (en) | 2006-02-01 | 2009-06-24 | Burnham Inst Medical Research | LYMPH ADDRESS CODES FOR TUMORS AND PREMALARY LESIONS |
| FI121959B (fi) | 2008-05-09 | 2011-06-30 | Pirjo Laakkonen | Aivokasvaimiin hakeutuva peptidi |
| TW201004658A (en) * | 2008-07-31 | 2010-02-01 | Enzon Pharmaceuticals Inc | Nanoparticle compositions for nucleic acids delivery system |
| TW201021852A (en) * | 2008-11-17 | 2010-06-16 | Enzon Pharmaceuticals Inc | Releasable fusogenic lipids for nucleic acids delivery systems |
| TW201021853A (en) * | 2008-11-17 | 2010-06-16 | Enzon Pharmaceuticals Inc | Releasable cationic lipids for nucleic acids delivery systems |
| WO2011005540A1 (en) | 2009-06-22 | 2011-01-13 | Burnham Institute For Medical Research | Methods and compositions using peptides and proteins with c-terminal elements |
| WO2011039646A2 (en) | 2009-09-30 | 2011-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Papilloma virus -like particles for targeted gene delivery |
| WO2011127405A1 (en) | 2010-04-08 | 2011-10-13 | Sanford-Burnham Medical Research Institute | Methods and compositions for enhanced delivery of compounds |
| WO2012118778A1 (en) | 2011-02-28 | 2012-09-07 | Sanford-Burnham Medical Research Institute | Truncated car peptides and methods and compositions using truncated car peptides |
| AU2012262488A1 (en) | 2011-05-31 | 2014-01-16 | Airware, Inc. | Re-calibration of AB NDIR gas sensors |
| WO2016172515A1 (en) | 2015-04-23 | 2016-10-27 | Sanford Burnham Prebys Medical Discovery Institute | Targeted delivery system and methods of use therefor |
| GB201710097D0 (en) * | 2017-06-23 | 2017-08-09 | Univ Ulster | A sensitizer - peptide conjugate |
| WO2023064887A1 (en) | 2021-10-15 | 2023-04-20 | The Board Of Trustees Of The University Of Illinois | Mechanochemical dynamic therapy for focal cancer treatment |
| WO2024115720A1 (en) * | 2022-12-01 | 2024-06-06 | Hairvel Oü | Novel peptide conjugates |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2156581T5 (es) * | 1998-03-30 | 2015-01-21 | Northwest Biotherapeutics, Inc. | Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| EP1383883A2 (en) * | 2001-04-24 | 2004-01-28 | Isis Innovation Limited | Asthma-associated snps around microsatellite marker d2s308 and identification of human prolyl-oligopeptidase-dpp10 |
| EP1581790B1 (en) | 2001-11-08 | 2009-01-07 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
| US7723474B2 (en) | 2003-10-21 | 2010-05-25 | The Regents Of The University Of California | Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies |
| EP1996607A4 (en) | 2006-02-01 | 2009-06-24 | Burnham Inst Medical Research | LYMPH ADDRESS CODES FOR TUMORS AND PREMALARY LESIONS |
-
2007
- 2007-02-01 EP EP07762715A patent/EP1996607A4/en not_active Withdrawn
- 2007-02-01 US US11/670,318 patent/US7919466B2/en not_active Expired - Fee Related
- 2007-02-01 CA CA002638807A patent/CA2638807A1/en not_active Abandoned
- 2007-02-01 JP JP2008553510A patent/JP2009525055A/ja active Pending
- 2007-02-01 WO PCT/US2007/061480 patent/WO2007090194A2/en not_active Ceased
-
2011
- 2011-02-10 US US13/024,445 patent/US8536132B2/en not_active Expired - Fee Related
-
2013
- 2013-09-13 US US14/026,377 patent/US8951971B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525055A5 (https=) | ||
| JP7007423B2 (ja) | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 | |
| JP2010508022A5 (https=) | ||
| Wadia et al. | Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer | |
| Chittenden et al. | The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein | |
| McBride et al. | The carboxy‐terminal domain shared by the bovine papillomavirus E2 transactivator and repressor proteins contains a specific DNA binding activity. | |
| Dombroski et al. | Polypeptides containing highly conserved regions of transcription initiation factor σ70 exhibit specificity of binding to promoter DNA | |
| Wendler et al. | Identification of pirin, a novel highly conserved nuclear protein | |
| WO2012090150A2 (en) | New cell-penetrating peptides and uses thereof | |
| Yang et al. | HIV‐1 TAT‐mediated protein transduction and subcellular localization using novel expression vectors1 | |
| JP7312948B2 (ja) | Ａｔｆ５ペプチド多様体及びそれらの使用 | |
| WO1999033963A1 (en) | Metastatic cancer regulated gene | |
| Wierzbicki et al. | Protein and siRNA delivery by transportan and transportan 10 into colorectal cancer cell lines | |
| EP2493913B1 (en) | High stability streptavidin mutant proteins | |
| US6903077B1 (en) | Methods and products for delivering nucleic acids | |
| JP2012501165A5 (https=) | ||
| Peng et al. | Characterization of the Protein Product Encoded by a Splicing Variant of the Marek's Disease VirusEco-Q Gene (Meq) | |
| JP2010529843A (ja) | バイオマーカーおよび薬物標的としての、転写因子複合体の構成要素のがん関連アイソフォーム | |
| IL209595A (en) | Isolated nucleic acid, expression vector and host cell containing it, isolated polypeptide encoded by it and chimeric polypeptide containing it, process for preparation, oligopeptide hhipl l2 mimics loop, preparations containing it and methods for its production | |
| US20020151686A1 (en) | Recombinant soluble adenovirus receptor | |
| WO2000040723A2 (en) | Methods and products for delivering nucleic acids | |
| Langedijk et al. | New transport peptides broaden the horizon of applications for peptidic pharmaceuticals | |
| Albarran et al. | Efficient intracellular delivery of a pro-apoptotic peptide with a pH-responsive carrier | |
| Kruse et al. | The multi-KH protein vigilin associates with free and membrane-bound ribosomes | |
| WO1996004926A1 (en) | TWO NON-CONTIGUOUS REGIONS CONTRIBUTE TO NIDOGEN BINDING TO A SINGLE EGF-LIKE MOTIF OF THE LAMININ η1 CHAIN |